Glenmark Pharmaceuticals has announced that GRC 27864 is entering human trials. GRC 27864 targets Microsomal Prostaglandin E synthase-1 (mPGES-1) as a therapeutic target in pain management. Selective mPGES-1 inhibitors are expected to inhibit increased prostaglandin E2 (PGE2) production in the disease state without affecting other prostanoid metabolites and, consequently, may be devoid of the GI (gastrointestinal) and cardiovascular side effects seen with NSAIDs and COX-2 inhibitors, respectively.
Recent reports indicate that more than 1.5 billion people worldwide suffer from chronic pain in some form with a direct correlation between incidence rates and increasing age. It is estimated that, at some point in their lives, 20% of the global adult population suffers from pain with 10% of newly diagnosed cases of chronic pain being added each year.
Despite incremental advances in opioid-based or cyclooxygenase-based therapies, there has been little success in identifying and developing treatments based upon new targets that might overcome the limitations of currently available analgesic treatments for the management of chronic pain.
Glenmark has completed preclinical studies and Phase 1 enabling GLP studies for its selected lead molecule, GRC 27864 and has filed a Phase 1 application for first-in-human trial with the MHRA, UK. The Phase 1 studies are to be initiated soon and are likely to get completed by January 2015. Following this, Glenmark will also be initiating a proof of concept study in patients with acute pain.
PGE2 is a lipid mediator produced by arachidonic acid, which serves pivotal functions in disease conditions associated with fever, inflammation, and pain. mPGES-1 is a terminal enzyme in the PGE2 biosynthetic pathway and solely responsible for PGE2 synthesis during inflammation. Over expression of mPGES-1 is observed in various nonclinical animal models, such as RA, OA, atherosclerosis, experimental autoimmune encephalomyelitis, cancer, inflammatory bowel disease, multiple sclerosis, periodontitis, fibrosis, Parkinson's disease, and Alzheimer's disease.
On the contrary, mPGES-1 deleted cells produced significantly lower levels of PGE2 in response to inflammatory stimuli and were less sensitive to inflammatory and neuropathic pain, and refractory to the development of joint pathology in rodent arthritis models. Selective mPGES-1 inhibitors are expected to inhibit increased PGE2 production in the disease state without affecting other prostanoid metabolites and are, consequently, may be devoid of the GI and cardiovascular side effects seen with NSAIDs and COX-2 inhibitors, respectively, potentially making them suitable for chronic treatment of inflammatory diseases that are accompanied with pain.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- The Number Of My Publications Has Four Digits
- Professor Frenkel: Why Shouldn't We Drop Algebra From Our Education System?
- Metal Hip Replacements Implanted Since 2006 More Prone To Failure
- Does lower literacy make you a sucker for online health ads?
- Matter Can Potentially Accelerate The Expansion Of The Universe
- Unique Fragment From Earth’s Formation Returns Home
- Why Fraternal Twins Run In Families
- "I have space-time numbers. I don't have a metric space which, yes, requires a metric tensor for..."
- "Even using Wikipedia, an illustration of the conventional prejudice on the matter energy density..."
- "In Reading University Library there is a most interesting book Felix Klein and Sophus Lie by I..."
- "Correction (will merge this into the article later): Orange dwarf stars have lifetimes of 15 -..."
- "Lobos, after what you say about academia, I still wander why you keep the Harvard Veritas coat..."
- Parents' presence at bedside found to decrease neonatal abstinence syndrome severity
- Breastfeeding app shows promise in supporting first-time mothers
- Study shows asthma-related Twitter posts can predict rise in hospital visits
- Mental health diagnoses rise significantly for military children
- Combination of face-to-face and online bullying may pack a powerful punch